CD8A and hepatocellular carcinoma: Taken together, we demonstrate that MDZ shapes an immune-enhancing tumour microenvironment by restricting PD-L1 expression and reducing the depletion of CD8+ T cells in HCC, suggesting that MDZ is a potential antitumor drug.